Common Contracts

EX-10.21 21 dex1021.htm EXCLUSIVE LICENSE AGREEMENT, DANA-FARBER CANCER INSTITUTE, INC. Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT

Exclusive License Agreement • May 5th, 2020 • Massachusetts

• Contract Type
  Exclusive License Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Massachusetts

This agreement, effective as of March 19, 2002 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 44 Binney Street, Boston, Massachusetts, 02115 (“DFCI”) and GenPath Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT

Exclusive License Agreement • December 16th, 2009 • Aveo Pharmaceuticals Inc • Massachusetts

• Contract Type
  Exclusive License Agreement
• Filed
  December 16th, 2009
• Company
  Aveo Pharmaceuticals Inc
• Jurisdiction
  Massachusetts

This agreement, effective as of March 19, 2002 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 44 Binney Street, Boston, Massachusetts, 02115 (“DFCI”) and GenPath Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).